公开(公告)号：US20060058272A1

公开(公告)日：2006-03-16

申请号：US11266395

申请日：2005-11-04

申请人： Juergen Hilman ,  Wolfgang Heil ,  Ralph Lipp ,  Renate Heithecker

发明人： Juergen Hilman ,  Wolfgang Heil ,  Ralph Lipp ,  Renate Heithecker

IPC分类号： A61K31/56

CPC分类号： A61K31/585 ,  A61K31/56 ,  A61K31/567 ,  A61K2300/00

摘要： A pharmaceutical composition comprises, as a first active agent, 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.

公开(公告)号：US06787531B1

公开(公告)日：2004-09-07

申请号：US09654227

申请日：2000-08-31

申请人： Juergen Hilman ,  Wolfgang Heil ,  Ralph Lipp ,  Renate Heithecker ,  Michael Huempel ,  Johannes W. Tack

发明人： Juergen Hilman ,  Wolfgang Heil ,  Ralph Lipp ,  Renate Heithecker ,  Michael Huempel ,  Johannes W. Tack

IPC分类号： A61K3156

CPC分类号： A61K31/585 ,  A61K31/56 ,  A61K31/567 ,  A61K2300/00

摘要： A pharmaceutical composition comprises, as a first active agent, 6&bgr;,7&bgr;;15&bgr;,16&bgr;-dimethylene-3-oxo-17&agr;-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17&agr;-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.

摘要翻译： 作为第一活性剂的药物组合物包含对应于每日剂量的量的6β，7beta，15beta，16beta-二亚甲基-3-氧代-17α-孕-4-烯-21,17-碳内酯（屈螺酮） 在约2mg至约4mg的施用组合物上，并且作为第二活性剂，以对应于约0.01mg至约0.05mg的日剂量的量的17α-炔炔雌二醇（炔雌醇）与 一个或多个药学上可接受的载体或赋形剂。在一个具体实施方案中，组合物由多个单独包装的和单独可移除的每日剂量单位组成，放置在包装单元中并且用于口服给药至少连续21天，其中 所述日剂量单位包括屈螺酮和炔雌醇的组合。 该组合物可以进一步包含7个或更少的不含活性剂或仅含有炔雌醇的日剂量单位。